Because early treatment choice is critical in first-episode schizophrenia-spectrum disorders
(FES), this meta-analysis compared efficacy and tolerability of individual second-generation …

Objectives: To assess the methods and reporting of cardiometabolic outcome studies of the
first treated episode of psychosis, review key findings, and suggest directions for future …

BackgroundThere is an ongoing debate about the use of atypical antipsychotics as a first-
line treatment for first-episode psychosis. AimsTo examine the evidence base for this …

Guidelines for schizophrenia treatment have been created in various countries and have
been translated and used in Japan as well. However, the available drugs and their …

This article reviews evidence that researchers and mental health service providers need to
take into account four modifiable factors that affect the prevalence of the metabolic syndrome …

BackgroundWeight gain is a long-recognized side-effect of antipsychotic (AP) drugs and a
major health concern in the treatment of psychosis. The strength of the causal relationship …

Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder of the hair
follicles, and has been associated with a multitude of systemic disorders and pathologies …

Cardiovascular morbidity and mortality are important problems among patients with
schizophrenia. A wide spectrum of reasons, ranging from genes to the environment, are held …

Background: Persons with schizophrenia are reported to be more likely to die from
cardiovascular illness than those in the general population, and are at a greater risk of …

Background: Antipsychotic-induced weight gain is one of the most distressing adverse
effects being observed in recent times. Most studies have been limited by several …